BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33390782)

  • 1. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
    Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
    Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
    Simioni C; Cani A; Martelli AM; Zauli G; Tabellini G; McCubrey J; Capitani S; Neri LM
    Oncotarget; 2014 Oct; 5(20):10034-47. PubMed ID: 25296981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two mTOR inhibitors, rapamycin and Torin 1, differentially regulate iron-induced generation of mitochondrial ROS.
    Huang H; Chen J; Lu H; Zhou M; Chai Z; Hu Y
    Biometals; 2017 Dec; 30(6):975-980. PubMed ID: 29063293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
    Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
    Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE; Ducker GS; Feldman ME; Bergsland EK; Warren RS; Shokat KM
    Invest New Drugs; 2012 Dec; 30(6):2219-25. PubMed ID: 22270257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth.
    Wang C; Wang X; Su Z; Fei H; Liu X; Pan Q
    Oncol Rep; 2015 Oct; 34(4):1708-16. PubMed ID: 26239364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.
    Caro-Vegas C; Bailey A; Bigi R; Damania B; Dittmer DP
    mBio; 2019 Feb; 10(1):. PubMed ID: 30782662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
    Zhang H; Dou J; Yu Y; Zhao Y; Fan Y; Cheng J; Xu X; Liu W; Guan S; Chen Z; shi Y; Patel R; Vasudevan SA; Zage PE; Zhang H; Nuchtern JG; Kim ES; Fu S; Yang J
    Apoptosis; 2015 Jan; 20(1):50-62. PubMed ID: 25425103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
    Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.
    Li Z; Yan S; Attayan N; Ramalingam S; Thiele CJ
    Clin Cancer Res; 2012 Jul; 18(13):3603-15. PubMed ID: 22550167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
    Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
    Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
    Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
    Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells.
    Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P
    Tumour Biol; 2017 Mar; 39(3):1010428317695921. PubMed ID: 28351321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.